Clofarabine-associated acute kidney injury in patients undergoing hematopoietic stem cell transplant

References

• Kantarjian H, Gandhi V, Cortes J, et al. Phase 2 clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemia. Blood 2003;102:2379–2386.
   PubMed Web of Science ®Google Scholar
• Nabhan C, Davis N, Bitran JD, et al. Efficacy and safety of clofarabine in relapsed and/or refractory non-hodgkin lymphoma, including rituximab-refractory patients. Cancer 2011;117:1490–1497.
   PubMed Web of Science ®Google Scholar
• Faderl S, Ravandi F, Huang X, et al. A randomized study of clofarabine versus clofarabine plus low-dose cytarabine as front-line therapy for patients aged 60 years and older with acute myeloid leukemia and high-risk myelodysplastic syndrome. Blood 2008;112:1638–1645.
   PubMed Web of Science ®Google Scholar
• Van Besien K, Stock W, Rich E, et al. Phase I-II study of clofarabine-melphalan-alemtuzumab conditioning for allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 2012;18:913–921.
   PubMed Web of Science ®Google Scholar
• Jeha S, Gandhi V, Chan KW, et al. Clofarabine, a novel nucleoside analog, is active in pediatric patients with advanced leukemia. Blood 2004;103:784–789.
   PubMed Web of Science ®Google Scholar
• CLOLAR® (clofarabine) label (last revised January 2013). Available from: http://products.sanofi.us/clolar/clolar.html
   Google Scholar
• Jeha S, Razzouk B, Rytting M, et al. Phase II study of clofarabine in pediatric patients with refractory or relapsed acute myeloid leukemia. J Clin Oncol 2009;27:4392–4397.
   PubMed Web of Science ®Google Scholar
• Kintzel PE, Visser JA, Campbell AD. Clofarabine-associated acute kidney injury and proteinuria. Pharmacotherapy 2011;31:923–923.
   PubMed Web of Science ®Google Scholar
• Faderl S, Garcia-Manero G, Jabbour E, et al. A randomized study of 2 dose levels of intravenous clofarabine in the treatment of patients with higher-risk myelodysplastic syndrome. Cancer 2012;118:722–728.
   PubMed Web of Science ®Google Scholar
• Farag SS, Wood LL, Schwartz JE, et al. Phase I trial and pharmacokinetic study of high-dose clofarabine and busulfan and allogeneic stem cell transplantation in adults with high-risk and refractory acute leukemia. Leukemia 2011;25:599–605.
   PubMed Web of Science ®Google Scholar
• Kirschbaum MH, Stein AS, Popplewell L, et al. A phase I study in adults of clofarabine combined with high-dose melphalan as reduced-intensity conditioning for allogeneic transplantation. Biol Blood Marrow Transplant 2012;18:432–440.
   PubMed Web of Science ®Google Scholar
• Claxton D, Erba HP, Faderl S, et al. Outpatient consolidation treatment with clofarabine in a phase 2 study of older adult patients with previously untreated acute myelogenous leukemia. Leuk Lymphoma 2012;53:435–440.
   PubMed Web of Science ®Google Scholar
• American Society for Blood and Marrow Transplantation Request for Information Disease Classifications [Internet]. Chicago, IL: University of Chicago; 2013. Available from: http://asbmt.org/displaycommon.cfm?an = 1&subarticlenbr = 35
   Google Scholar
• Gandhi V, Plunkett W. Cellular and clinical pharmacology of fludarabine. Clin Pharmacokinet 2002;15(41):93–103.
   Web of Science ®Google Scholar
• Mehta RL, Kellum JA, Shah SV, et al. Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury. Crit Care 2007;11:R31.
   PubMed Web of Science ®Google Scholar
• Levey AS, Coresh J, Greene T, et al. Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med 2006;145:247–254.
   PubMed Web of Science ®Google Scholar
• Delaigle A, Hall P, Jin J. Robustness and accuracy of methods for high dimensional data analysis based on Student's t-statistic. J R Stat Soc B 2011;73:283–301.
   Google Scholar
• Cao H. Moderate deviations for two sample t-statistics. ESAIM: Probability and Statistics 2007;11:264–271.
   Google Scholar
• Rosner, B. Fundamentals of biostatistics. 6th ed. Belmont, CA: Thomson-Brooks/Cole; 2006. pp 557–629.
   Google Scholar
• Bonate P, Cunningham C, Gaynon P, et al. Population pharmacokinetics of clofarabine and its metabolite 6-ketoclofarabine in adult and pediatric patients with cancer. Cancer Chemother Pharmacol 2011;67:875–890.
   PubMed Web of Science ®Google Scholar
• Perrone RD, Madias NE, Levey AS. Serum creatinine as an index of renal function: new insights into old concepts. Clin Chem 1992;38:1933–1953.
   PubMed Web of Science ®Google Scholar
• Chang A, Hingorani S, Kowalewska J, et al. Spectrum of renal pathology in hematopoietic cell transplantation:a series of 20 patients and review of the literature. Clin J Am Soc Nephrol 2007;2:1014–1023.
   PubMed Web of Science ®Google Scholar
• Bardales RH. Practical urologic cytopathology. New York, NY: Oxford University Press; 2002. pp 557–629.
   Google Scholar
• Waring WS, Moonie A. Earlier recognition of nephrotoxicity using novel biomarkers of acute kidney injury. Clin Toxicol 2011;49:720–728.
   PubMed Web of Science ®Google Scholar
• Calvert AH, Newell DR, Gumbrell LA, et al. Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol 1989;7:1748–1756.
   PubMed Web of Science ®Google Scholar
• van Besien K, Artz A, Smith S, et al. Fludarabine, melphalan, and alemtuzumab conditioning in adults with standard-risk advanced acute myeloid leukemia and myelodysplastic syndrome. J Clin Oncol 2005;23:5728–5738.
   PubMed Web of Science ®Google Scholar
• O’Donnell PH, Artz AS, Undevia SD, et al. Phase I study of dose-escalated busulfan with fludarabine and alemtuzumab as conditioning for allogeneic hematopoietic stem cell transplant: reduced clearance at high doses and occurrence of late sinusoidal obstruction syndrome/veno-occlusive disease. Leuk Lymphoma 2010;51:2154–2156.
   PubMed Web of Science ®Google Scholar
• van Besien K, Schouten V, Parsad S, et al. Allogeneic stem cell transplant in renal failure:engraftment and prolonged survival, but high incidence of neurologic toxicity. Leuk Lymphoma 2012;53:158–159.
   PubMed Web of Science ®Google Scholar
• Stevens LA, Coresch J, Greene T et al. Assessing kidney function—measured and estimated glomerular filtration rate. N Engl J Med 2006;354:2473–2483.
   PubMed Web of Science ®Google Scholar
• Glassock RJ, Winearls C. Ageing and the glomerular filtration rate: truths and consequences. Trans Am Clin Climatol Assoc 2009;120: 419–428.
   PubMedGoogle Scholar